Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 23 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Notice of ceasing to be a substantial holder
Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Notice of change of interests of initial substantial holder
Melbourne, Australia, 25 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Notice of initial substantial holder
Melbourne, Australia, 20 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 12 May 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL progresses vitiligo study
CLINUVEL today announced that it will start treatment of vitiligo patients with...
Read More
Notification regarding unquoted securities
Melbourne, Australia, 6 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
CEO letter
For the benefit of the 2.5% recently joined shareholders, I distinguish CLINUVEL’s...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
Notice of ceasing to be a substantial holder
Melbourne, Australia, 27 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Initial Director’s Interest Notice
Melbourne, Australia, 7 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL appoints new Non-Executive Director
Melbourne, Australia, 04 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Change of Director's Interest Notice
Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More